​

iRhythm (IRTC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

IRTC Stock Forecast

iRhythm (IRTC) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $133.00, with a high of $146.00 and a low of $120.00. This represents a -8.58% decline from the last price of $145.48.

$70 $86 $102 $118 $134 $150 High: $146 Avg: $133 Low: $120 Last Closed Price: $145.48

IRTC Stock Rating

iRhythm stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (83.33%), 3 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 3 15 Strong Sell Sell Hold Buy Strong Buy

IRTC Price Target Upside V Benchmarks

TypeNameUpside
StockiRhythm-8.58%
SectorHealthcare Stocks 23.68%
IndustryMedical Device Stocks16.34%

Price Target Trends

1M3M12M
# Anlaysts-113
Avg Price Target-$146.00$114.46
Last Closing Price$145.48$145.48$145.48
Upside/Downside-0.36%-21.32%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25391--13
May, 25382--13
Apr, 25382--13
Mar, 25382--13
Feb, 25382--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 05, 2025Richard NewitterTruist Financial$146.00$135.767.54%0.36%
Jan 08, 2025Suraj KaliaOppenheimer$120.00$90.5732.49%-17.51%
Oct 31, 2024Michael MatsonNeedham$96.00$75.7726.70%-34.01%
Oct 22, 2024David RescottTruist Financial$95.00$62.1052.98%-34.70%
Oct 15, 2024David RescottRobert W. Baird$100.00$57.9472.59%-31.26%
Oct 14, 2024Richard NewitterTruist Financial$80.00$57.5838.94%-45.01%
Oct 04, 2024David RomanGoldman Sachs$78.00$66.2817.68%-46.38%
Sep 25, 2024William PlovanicCanaccord Genuity$137.00$70.3094.88%-5.83%
Aug 02, 2024Richard NewitterTruist Financial$117.00$75.4455.09%-19.58%
Aug 02, 2024Suraj KaliaOppenheimer$145.00$84.2272.17%-0.33%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 22, 2025CitigroupBuyBuyhold
May 02, 2025Wells FargoOverweightOverweightupgrade
Jan 08, 2025OppenheimerOutperformOutperformhold
Oct 31, 2024NeedhamBuyBuyhold
Oct 22, 2024OppenheimerOutperformOutperformhold
Oct 22, 2024BTIGBuyBuyhold
Oct 04, 2024Goldman SachsNeutralinitialise
Aug 02, 2024OppenheimerOutperformOutperformhold
Aug 02, 2024BTIGBuyBuyhold
Jun 20, 2024Wolfe ResearchOutperformupgrade

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.58$-3.46$-3.88$-4.04$-3.63----
Avg Forecast$-1.53$-3.52$-3.46$-3.10$-3.63$-1.83$-0.79$0.73$1.50
High Forecast$-1.52$-3.49$-3.43$-2.81$-3.41$-1.29$-0.32$0.73$1.51
Low Forecast$-1.54$-3.55$-3.50$-3.29$-3.83$-2.23$-1.04$0.72$1.48
Surprise %3.27%-1.70%12.14%30.32%-----

Revenue Forecast

$250M $430M $610M $790M $970M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$265.17M$322.82M$410.92M$492.68M$591.84M----
Avg Forecast$263.12M$319.68M$408.46M$490.37M$584.97M$679.59M$796.87M$959.05M$1.12B
High Forecast$264.41M$321.25M$412.02M$493.74M$589.84M$682.68M$797.12M$963.15M$1.13B
Low Forecast$261.09M$317.22M$405.59M$489.34M$582.95M$675.49M$796.63M$951.39M$1.11B
Surprise %0.78%0.98%0.60%0.47%1.17%----

Net Income Forecast

$-200M $-150M $-100M $-50M $0 $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-43.83M$-101.36M$-116.16M$-123.41M$-113.29M----
Avg Forecast$-49.37M$-112.19M$-161.43M$-123.41M$-110.56M$-56.63M$-26.69M$22.23M$45.79M
High Forecast$-39.50M$-89.75M$-129.15M$-98.72M$-104.12M$-39.26M$-9.79M$22.41M$46.05M
Low Forecast$-59.25M$-134.62M$-193.72M$-148.09M$-117.01M$-68.06M$-31.89M$22.05M$45.32M
Surprise %-11.23%-9.65%-28.05%-2.47%----

IRTC Forecast FAQ

Is iRhythm stock a buy?

iRhythm stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that iRhythm is a favorable investment for most analysts.

What is iRhythm's price target?

iRhythm's price target, set by 18 Wall Street analysts, averages $133 over the next 12 months. The price target range spans from $120 at the low end to $146 at the high end, suggesting a potential -8.58% change from the previous closing price of $145.48.

How does iRhythm stock forecast compare to its benchmarks?

iRhythm's stock forecast shows a -8.58% downside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the medical device stocks industry (16.34%).

What is the breakdown of analyst ratings for iRhythm over the past three months?

  • June 2025: 23.08% Strong Buy, 69.23% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 23.08% Strong Buy, 61.54% Buy, 15.38% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 23.08% Strong Buy, 61.54% Buy, 15.38% Hold, 0% Sell, 0% Strong Sell.

What is iRhythm’s EPS forecast?

iRhythm's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.83, marking a -49.59% decrease from the reported $-3.63 in 2024. Estimates for the following years are $-0.79 in 2026, $0.73 in 2027, and $1.5 in 2028.

What is iRhythm’s revenue forecast?

iRhythm's average annual revenue forecast for its fiscal year ending in December 2025 is $679.59M, reflecting a 14.83% increase from the reported $591.84M in 2024. The forecast for 2026 is $796.87M, followed by $959.05M for 2027, and $1.12B for 2028.

What is iRhythm’s net income forecast?

iRhythm's net income forecast for the fiscal year ending in December 2025 stands at $-56.633M, representing a -50.01% decrease from the reported $-113M in 2024. Projections indicate $-26.694M in 2026, $22.23M in 2027, and $45.79M in 2028.